Published in Curr Psychiatry Rep on August 01, 2007
Personalized medicine in psychiatry: problems and promises. BMC Med (2013) 1.09
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Pharmacogenetics of antipsychotics. Can J Psychiatry (2014) 1.02
Knowledge and attitudes about personalized mental health genomics: narratives from individuals coping with serious mental illness. Community Ment Health J (2011) 0.89
Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs. J Comp Eff Res (2012) 0.76
Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. Psychopharmacology (Berl) (2010) 0.76
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. Biomed Res Int (2015) 0.75
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science (2006) 6.71
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry (2007) 2.70
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics (2005) 1.97
Tardive dyskinesia circa 2006. Am J Psychiatry (2006) 1.78
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res (2006) 1.65
Pharmacogenetics of psychotropic drug response. Am J Psychiatry (2004) 1.61
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit (2006) 1.45
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci (2002) 1.11
Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am (2006) 1.10
The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther (2006) 1.07
Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res (1998) 1.05
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J (2003) 0.95
The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.94
The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology (2006) 0.93
Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) (2004) 0.92
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry (2001) 0.91
Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry (2006) 0.90
Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol (2005) 0.89
The structures of MsbA: Insight into ABC transporter-mediated multidrug efflux. FEBS Lett (2005) 0.88
The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev (2006) 0.86
Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol (2005) 0.86
Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry (2001) 0.85
A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J (2006) 0.85
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry (2002) 0.85
Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol (2004) 0.85
Pharmacogenetics in mood disorder. Curr Opin Psychiatry (2005) 0.84
Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics (2006) 0.84
Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics (2005) 0.83
Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics (1998) 0.82
Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics (2006) 0.81
Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res (2000) 0.81
Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet (2002) 0.81
Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res (2006) 0.78
CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest (2006) 0.78
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.78
Towards more effective antipsychotic treatment. Br J Psychiatry Suppl (1994) 0.77
Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol (2006) 0.77
Genetics and psychopharmacology: prospects for individualized treatment. Essent Psychopharmacol (2005) 0.77
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron (2011) 3.08
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum Mol Genet (2008) 1.60
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. Neuron (2011) 1.57
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res (2010) 1.55
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry (2005) 1.49
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry (2009) 1.47
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? J Clin Psychiatry (2011) 1.42
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis (2006) 1.38
Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res (2010) 1.35
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry (2010) 1.33
High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 1.33
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
White matter development in adolescence: diffusion tensor imaging and meta-analytic results. Schizophr Bull (2012) 1.25
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
Sex differences in frontal lobe white matter microstructure: a DTI study. Neuroreport (2003) 1.23
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol Psychiatry (2006) 1.22
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology (2004) 1.21
DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol (2007) 1.21
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res (2006) 1.20
DISC1 and neurocognitive function in schizophrenia. Neuroreport (2005) 1.19
Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry (2006) 1.17
Abnormal temporal lobe white matter as a biomarker for genetic risk of bipolar disorder. Biol Psychiatry (2012) 1.16
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology (2011) 1.15
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct (2005) 1.14
Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry (2003) 1.14
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr Bull (2008) 1.11
Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am (2006) 1.10
COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord (2007) 1.08
Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. Genome Biol (2012) 1.08
A voxel-based diffusion tensor imaging study of white matter in bipolar disorder. Neuropsychopharmacology (2009) 1.06
Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry (2013) 1.05
Resting-state fMRI connectivity impairment in schizophrenia and bipolar disorder. Schizophr Bull (2013) 1.04
In vivo microRNA detection and quantitation in cerebrospinal fluid. J Mol Neurosci (2012) 1.02
The role of COMT Val158Met in cognition. Biol Psychiatry (2008) 0.99
Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol (2009) 0.98
Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs (2007) 0.96
Metabolism and biochemical effects of nicotine for primary care providers. Med Clin North Am (2004) 0.95
Early identification and high-risk strategies for bipolar disorder. Bipolar Disord (2007) 0.95
Temperament and character dimensions in bipolar I disorder: a comparison to healthy controls. J Psychiatr Res (2008) 0.94
Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biol Psychiatry (2010) 0.94
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol (2015) 0.93
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics (2010) 0.93
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophr Bull (2015) 0.93
Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry (2007) 0.93
Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) (2004) 0.92
Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci (2009) 0.92
Sex differences in resilience to childhood maltreatment: effects of trauma history on hippocampal volume, general cognition and subclinical psychosis in healthy adults. J Psychiatr Res (2013) 0.91
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull (2015) 0.91
The role of general intelligence as an intermediate phenotype for neuropsychiatric disorders. Cogn Neuropsychiatry (2009) 0.90
Novel multi-nucleotide polymorphisms in the human genome characterized by whole genome and exome sequencing. Nucleic Acids Res (2010) 0.90
COMT genotype and manic symptoms in schizophrenia. Schizophr Res (2006) 0.89
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry (2009) 0.89
DTNBP1 is associated with imaging phenotypes in schizophrenia. Hum Brain Mapp (2009) 0.89
Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol (2012) 0.88
A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol (2011) 0.88
Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull (2012) 0.88
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr Res (2008) 0.88
Emotional modulation of response inhibition in stable patients with bipolar I disorder: a comparison with healthy and schizophrenia subjects. Bipolar Disord (2011) 0.88
Single-subject classification of schizophrenia using event-related potentials obtained during auditory and visual oddball paradigms. Eur Arch Psychiatry Clin Neurosci (2012) 0.87
Overlapping and distinct gray and white matter abnormalities in schizophrenia and bipolar I disorder. Bipolar Disord (2013) 0.87
Attention and psychomotor functioning in bipolar depression. Psychiatry Res (2009) 0.87
White matter abnormalities in pediatric obsessive-compulsive disorder. Neuropsychopharmacology (2012) 0.86
Judgements of agency in schizophrenia: an impairment in autonoetic metacognition. Philos Trans R Soc Lond B Biol Sci (2012) 0.85
Analysis of TBX1 variation in patients with psychotic and affective disorders. Mol Med (2007) 0.85
Convergent findings for abnormalities of the NF-κB signaling pathway in schizophrenia. Neuropsychopharmacology (2012) 0.85
Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry (2011) 0.85
Impulsivity in bipolar disorder: relationships with neurocognitive dysfunction and substance use history. Bipolar Disord (2013) 0.85
Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr Res (2013) 0.85
Pharmacogenetics in mood disorder. Curr Opin Psychiatry (2005) 0.84
Gray matter structural alterations in obsessive-compulsive disorder: relationship to neuropsychological functions. Psychiatry Res (2008) 0.84
QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry (2011) 0.83
A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol (2004) 0.83
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res (2013) 0.82
The COMT Met158 allele and violence in schizophrenia: a meta-analysis. Schizophr Res (2012) 0.82
The serotonin transporter gene and disease modification in psychosis: evidence for systematic differences in allelic directionality at the 5-HTTLPR locus. Schizophr Res (2009) 0.81
Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet (2002) 0.81
The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations. Neuropsychopharmacology (2006) 0.81